83.9 F
San Diego
Wednesday, Jul 24, 2024
-Advertisement-
Array

Mast Therapeutics Announces CMO’s Departure

Mast Therapeutics Inc. announced that Chief Medical Officer and Senior Vice President Santosh Vetticaden will be leaving the company in mid-September.

Edwin Parsley, the chief medical officer of Aires Pharmaceuticals Inc. acquired by Mast earlier this year, will assume Vetticaden’s former responsibilities as the company’s interim chief medical officer.

Parsley was previously with Pfizer Inc. where he oversaw clinical trials for Revatio. He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine and sleep medicine. Parsley has been actively engaged with Mast since Aires was acquired in February 2014.

“We want to thank Santosh for his many contributions and wish him the very best in his future endeavors,” said Brian Culley, chief executive officer of Mast. “Santosh has put in place a strong clinical operations group that has us well-positioned to advance our programs through late-stage development.”

Mast (NYSE MKT: MSTX) is a publicly traded biopharmaceutical company headquartered in San Diego. The Company is leveraging the Molecular Adhesion and Sealant Technology platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and nonpurified poloxamers, to develop a product candidate for serious or life-threatening diseases and conditions characterized by membrane dysfunction.

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-